Skip to main content

MINI REVIEW article

Front. Oncol.
Sec. Gynecological Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1503107
This article is part of the Research Topic Integrating Genetics and Proteomics for Drug Discovery View all articles

Mini Review: Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer

Provisionally accepted
Trudy J. Philips Trudy J. Philips 1Britt K. Erickson Britt K. Erickson 2Stefani Thomas Stefani Thomas 3*
  • 1 Department of Pharmacology, Medical School, University of Minnesota, Minneapolis, Minnesota, United States
  • 2 Department of Obstetrics, Gynecology and Women's Heath, Medical School, University of Minnesota, Minneapolis, Minnesota, United States
  • 3 Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minnesota, United States

The final, formatted version of the article will be published soon.

    Genomic analysis has played a significant role in the identification of driver mutations that are linked to disease progression and response to drug treatment in ovarian cancer. A prominent example is the stratification of epithelial ovarian cancer (EOC) patients with homologous recombination deficiency (HRD) characterized by mutations in DNA damage repair genes such as BRCA1/2 for treatment with PARP inhibitors. However, recent studies have shown that some epithelial ovarian tumors respond to PARP inhibitors irrespective of their HRD or BRCA mutation status. An exclusive focus on the genome overlooks the significant insight that can be gained from other biological analytes, including proteins, which carry out cellular functions. Proteogenomics is the integration of genomics, transcriptomics, epigenomics and proteomics data. This review paper provides novel insight into the role of proteogeonomics as an analytical approach to identify predictive biomarkers of drug treatment response in epithelial ovarian cancer. Proteogenomic analysis can facilitate the identification of predictive biomarkers of drug treatment response, consequently greatly improving the stratification of patients with EOC for treatment towards a goal of personalized medicine.

    Keywords: ovarian cancer, PARP inhibitior, proteogenomics, Immunotherapy, biomarkers, antibody drug conjugate (ADC)

    Received: 28 Sep 2024; Accepted: 12 Dec 2024.

    Copyright: © 2024 Philips, Erickson and Thomas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Stefani Thomas, Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minnesota, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.